Andrew joined Frazier Healthcare Partners in July 2023 as a Senior Associate on the Growth Buyout team. He is involved with several of Frazier's portfolio companies, including United Derm Partners.
Prior to joining Frazier, Andrew was a Senior Manager at Zymergen, a publicly traded biotechnology company that has since been acquired by Ginkgo Bioworks. At Zymergen, Andrew worked across a variety of functions, including mergers and acquisitions, business development, and early-stage product development.
Prior to Zymergen, Andrew was an Investment Banking Associate Director at UBS, where he focused on mergers and acquisitions and capital markets activities for large-cap healthcare companies. Andrew received his MBA from the Wharton School of the University of Pennsylvania and his BA in Economics from Yale University.
Wharton School of the University of Pennsylvania (MBA)
Yale University (BA, Economics)